{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:39:30Z","timestamp":1793176770240,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004861","name":"Mackay Memorial Hospital","doi-asserted-by":"publisher","award":["MMH-D-115-03"],"award-info":[{"award-number":["MMH-D-115-03"]}],"id":[{"id":"10.13039\/501100004861","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004319","name":"Shin Kong Wu Ho Su Memorial Hospital","doi-asserted-by":"publisher","award":["2025SKHADR004"],"award-info":[{"award-number":["2025SKHADR004"]}],"id":[{"id":"10.13039\/501100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jacl.2026.08.015","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T14:49:15Z","timestamp":1787410155000},"page":"2160-2171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Durable lipid-lowering beyond 10 years with lomitapide in homozygous familial hypercholesterolemia: A real-world experience in Taiwan"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6865-855X","authenticated-orcid":false,"given":"Chao-Feng","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hwa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0949-9026","authenticated-orcid":false,"given":"Min-Ji","family":"Charng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.jacl.2026.08.015_bib1","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.jacl.2026.08.015_bib2","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.jacl.2026.08.015_bib3","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jacl.2026.08.015_bib4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/joim.13577","article-title":"Genetic and molecular architecture of familial hypercholesterolemia","volume":"293","author":"Abifadel","year":"2023","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacl.2026.08.015_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.atherosclerosis.2019.06.905","article-title":"Expert group from the Spanish Arteriosclerosis Society. Toward a new clinical classification of patients with familial hypercholesterolemia: one perspective from Spain","volume":"287","author":"Masana","year":"2019","journal-title":"Atherosclerosis"},{"issue":"14","key":"10.1016\/j.jacl.2026.08.015_bib6","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx317","article-title":"Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol","volume":"39","author":"Thompson","year":"2018","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.jacl.2026.08.015_bib7","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacl.2026.08.015_bib8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/MOL.0000000000000853","article-title":"New algorithms for treating homozygous familial hypercholesterolemia","volume":"33","author":"Tromp","year":"2022","journal-title":"Curr Opin Lipidol"},{"issue":"2","key":"10.1016\/j.jacl.2026.08.015_bib9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacl.2026.08.015_bib10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacl.2015.11.011","article-title":"LOWER investigators. LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: rationale and design","volume":"10","author":"Blom","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"9860","key":"10.1016\/j.jacl.2026.08.015_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jacl.2026.08.015_bib12","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5551\/jat.45708","article-title":"Safety and efficacy of lomitapide in Japanese patients with homozygous familial hypercholesterolemia (HoFH): results from the AEGR-733-301 long-term extension study","volume":"26","author":"Nohara","year":"2019","journal-title":"J Atheroscler Thromb"},{"issue":"5","key":"10.1016\/j.jacl.2026.08.015_bib13","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/eurjpc\/zwab229","article-title":"Italian and European Working Group on Lomitapide in HoFH. Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study","volume":"29","author":"D'Erasmo","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2026.08.015_bib14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s13023-021-01999-8","article-title":"Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey","volume":"16","author":"D'Erasmo","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.jacl.2026.08.015_bib15","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s12325-017-0531-x","article-title":"Efficacy of lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world clinical experience in Italy","volume":"34","author":"D'Erasmo","year":"2017","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.jacl.2026.08.015_bib16","doi-asserted-by":"crossref","first-page":"402","DOI":"10.5551\/jat.38216","article-title":"Efficacy and safety of lomitapide in Japanese Patients with homozygous familial hypercholesterolemia","volume":"24","author":"Harada-Shiba","year":"2017","journal-title":"J Atheroscler Thromb"},{"issue":"2","key":"10.1016\/j.jacl.2026.08.015_bib17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2217\/fca-2023-0136","article-title":"Real-world safety and efficacy of lomitapide in homozygous familial hypercholesterolemia: interim report of special-use survey in Japan","volume":"20","author":"Harada-Shiba","year":"2024","journal-title":"Future Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2026.08.015_bib18","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s13023-024-03374-9","article-title":"Long-term effectiveness and safety of lomitapide in patients with homozygous familial hypercholesterolemia: an observational case series","volume":"19","author":"Suppressa","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.jacl.2026.08.015_bib19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.5551\/jat.62773","article-title":"Genetic analysis in a Taiwanese cohort of 750 index patients with clinically diagnosed familial hypercholesterolemia","volume":"29","author":"Huang","year":"2022","journal-title":"J Atheroscler Thromb"},{"issue":"5","key":"10.1016\/j.jacl.2026.08.015_bib20","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jceh.2020.11.004","article-title":"Quantification of liver fat by MRI-PDFF imaging in patients with suspected non-alcoholic fatty liver disease and its correlation with metabolic syndrome, liver function test and ultrasonography","volume":"11","author":"Rodge","year":"2021","journal-title":"J Clin Exp Hepatol"},{"issue":"4","key":"10.1016\/j.jacl.2026.08.015_bib21","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.STR.30.4.841","article-title":"Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study","volume":"30","author":"Ebrahim","year":"1999","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.jacl.2026.08.015_bib22","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jacl.2026.01.013","article-title":"A nationwide genetic and phenotypic spectrum of 63 probands of homozygous familial hypercholesterolemia in Taiwan","volume":"20","author":"Lin","year":"2026","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2026.08.015_bib23","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jacl.2020.08.006","article-title":"Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)","volume":"14","author":"Underberg","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2026.08.015_bib24","first-page":"775","article-title":"Long-term experience with lomitapide treatment in patients with homozygous familial hypercholesterolemia: over 10 years of efficacy and safety data","volume":"19","author":"Arca","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.08.015_bib25","unstructured":"Food and Drug Administration. JUXTAPID\u00ae (lomitapide) product information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/203858s019lbl.pdf. Accessed December 27, 2025."},{"issue":"2","key":"10.1016\/j.jacl.2026.08.015_bib26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.atherosclerosis.2006.01.002","article-title":"Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia","volume":"189","author":"Amundsen","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.08.015_bib27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.atherosclerosis.2016.10.018","article-title":"Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: seven case series and discussion","volume":"254","author":"Ogura","year":"2016","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.jacl.2026.08.015_bib28","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/MOL.0000000000000790","article-title":"Management of familial hypercholesterolemia in pregnancy","volume":"32","author":"Graham","year":"2021","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2026.08.015_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.117516","article-title":"Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: the SAFEHEART follow-up study","volume":"393","author":"Alonso","year":"2024","journal-title":"Atherosclerosis"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:26:55Z","timestamp":1793176015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426004915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1933287426004915"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.08.015","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durable lipid-lowering beyond 10 years with lomitapide in homozygous familial hypercholesterolemia: A real-world experience in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}